Stocks-VRTX-Vertex Pharmaceuticals Incorporated

VRTX Vertex Pharmaceuticals Incorporated

481.44 2.80 (0.58%)
Market OpenDelayed Prices By NASDAQ, in USD
Trade
Stocks-VRTX-Vertex Pharmaceuticals Incorporated
VRTX Vertex Pharmaceuticals Incorporated
Trade

Overview

Prev Close 478.65
Day's Range 477.43 - 482.06
52 Week Range 341.40 - 509.49
Average Volume (3M) 1.15M
1-Year Return 39.22%
Beta0.6074
Market Cap 123.54B
P/E Ratio-236.28
Revenue10.32B
EPS-2.0258
Dividend (Yield) 0 (0%)
Sector
Health Technology
Industry
Pharmaceuticals Major
CEO
Reshma Kewalramani, MD
Employees
5,400

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2023: Vertex Pharmaceuticals Incorporated's revenues increased by 10.51% and amounted to 9.87B. Net income increased by 8.96% to 3.62B. Net assets increased by 26.36% to 17.58B and EPS increased from 12.82 to 13.89.
VRTX's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Created with Highcharts 4.2.7 /Highstock 4.2.7Total RevenueNet Income09/2312/2303/2406/24-4B-2B02B4B
Gross Margin
86.43%
Net Profit Margin
35.54%
Operating Margin
-3.79%
Return On Investment
21.90%
09/23
12/23
03/24
06/24
Total Revenue
2.48B
2.52B
2.69B
2.65B
Gross Profit
2.16B
2.15B
2.35B
2.28B
Operating Income
1.04B
958.8M
1.22B
1.14B
Net Income
1.04B
968.8M
1.1B
-3.59B